公开(公告)号：KR1020060017929A

公开(公告)日：2006-02-28

申请号：KR1020040061481

申请日：2004-08-04

Applicant: 동화약품주식회사

Inventor： 이진수 ,  안석훈 ,  진영구 ,  진상미 ,  박휘정 ,  구세광 ,  황연하 ,  김판수 ,  이순신 ,  유제만

IPC: C07D277/22

CPC classification number: C07D417/06 ,  C07D277/24 ,  C07D277/28 ,  C07D277/40 ,  C07D277/42 ,  C07D277/46 ,  C07D277/48 ,  C07D277/52 ,  C07D417/04 ,  C07D417/12

Abstract: 본 발명은 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학 조성물에 관한 것이다.
본 발명의 티아졸 유도체가 치환된 벤즈아미딘 유도체는 매우 낮은 농도에서 파골세포에 대한 분화를 효과적으로 억제하며, 조골세포에 대한 활성이 우수하여 골다공증의 예방 및 치료에 유용하게 사용될 수 있다. 또한, 본 발명의 티아졸 유도체가 치환된 벤즈아미딘 유도체는 골절시 형성된 가골의 소실 및 가골의 골화를 촉진시켜 골절 치료제로 유용하게 사용될 수 있으며, 천식시 유발되는 만성염증을 감소시킴으로, 천식을 포함한 알러지성 염증성 질환의 예방 및 치료에 유용하게 사용할 수 있다.
벤즈아미딘 유도체

公开(公告)号：KR1020020056565A

公开(公告)日：2002-07-10

申请号：KR1020000085947

申请日：2000-12-29

Applicant: 동화약품주식회사 ,  학교법인 포항공과대학교

Inventor： 정용호 ,  유제만 ,  황연하 ,  윤제인 ,  오병하 ,  차선신 ,  임경묵

IPC: C12N15/63

CPC classification number: C07K14/70575 ,  C07K2299/00

Abstract: PURPOSE: Provided are a three-dimensional structure of TRAIL-sDR5 complex of a human derived apoptotic factor and a receptor thereof by X-ray crystallography and TRAIL(TNF Related Apoptosis Inducing Ligand) deletion mutant protein. CONSTITUTION: TRAIL-sDR5 complex is prepared by mixing TRAIL protein of SEQ ID NO:1 and sDR5 protein of SEQ ID NO:2. It can be crystallization method comprises the steps of: injecting a solution consisting of 16% of polyethyleneglycol 3000, 0.05M of sodium acetate(pH 4.5), 0.22 M of sodium acetate and 0.6M of sodium chloride into a well; mixing the precipitation solution and protein solution in a mixing ratio of 1:1 on the surface of a cover slip; and covering the well with the cover slip to crystallize the protein.

Abstract translation: 目的：提供通过X射线晶体学和TRAIL（TNF相关凋亡诱导配体）缺失突变蛋白的人源性凋亡因子及其受体的TRAIL-sDR5复合物的三维结构。 构成：通过混合SEQ ID NO：1的TRAIL蛋白和SEQ ID NO：2的sDR5蛋白来制备TRAIL-sDR5复合物。 结晶方法包括以下步骤：将由16％聚乙二醇3000,0.05M乙酸钠（pH4.5），0.22M乙酸钠和0.6M氯化钠组成的溶液注入孔中; 将沉淀溶液和蛋白质溶液以1：1的混合比混合在盖板的表面上; 并用盖子覆盖井，使蛋白质结晶。

公开(公告)号：KR101747139B1

公开(公告)日：2017-06-14

申请号：KR1020140139734

申请日：2014-10-16

Applicant: 동화약품주식회사

Inventor： 윤주병 ,  이현용 ,  염지현 ,  김광현 ,  전지현 ,  장환봉 ,  황연하 ,  성승규 ,  최동락

IPC: A61K36/19 ,  A61P11/06 ,  A61P11/00

CPC classification number: A61K36/19 ,  A23L33/105 ,  A23V2002/00 ,  A61K8/9789 ,  A61K2236/33 ,  A61K2236/331 ,  A61K2236/35 ,  A61P1/12 ,  A61P11/02 ,  A61P17/00 ,  A61P27/14 ,  A61P27/16 ,  A61P37/08

Abstract: 본발명은쥐꼬리망초(justicia) 속식물의추출물또는분획물을유효성분으로포함하는알레르기성질환의예방, 치료또는개선용약학적조성물, 식품조성물및 화장료조성물에관한것이다. 본발명의쥐꼬리망초속 식물의추출물또는분획물은 IgE 항체분비를억제하며, 비만세포및 호염기구의탈과립 (degranulation)을억제할수 있고, 우수한항알레르기효과를나타내므로, 알레르기성질환을효과적으로예방, 치료또는개선할수 있다.

公开(公告)号：KR1020100067047A

公开(公告)日：2010-06-18

申请号：KR1020090119520

申请日：2009-12-04

Applicant: 동화약품주식회사

Inventor： 유제만 ,  이진수 ,  박휘정 ,  황연하 ,  김기윤

IPC: C07D213/72 ,  C07D213/64 ,  A61K31/44 ,  A61P19/10

CPC classification number: C07D213/74 ,  A61K31/4439 ,  C07D401/14

Abstract: PURPOSE: A 2,6-site-substituted 3-nitropyridine derivative compound is provided to suppress formation of osteroclast and to use in preventing and treating osteroporosis. CONSTITUTION: A novel 2,6-substituted 3-nitro derivative compound is denoted by chemical formula 1. A method for manufacturing the 2,6-substituted 3-nitro derivative compound comprises: a step of reating 2,6-dichloro-3-nitropyridine and 5-aminoindazole under the presence of base to prepare 2(1H-indazole-5-yl)amino-6-chloro-3-nitropyridine; and a step of reacting an amine compound of 2-methyl-2-imidazoline, 2-methyl imidazole, 2-isopropylimidazol, or 5-methyl imidazole with 2(1H-indazole-5-yl)amion-6-chloro-3-nitropyridine. A composition for preventing or treating osteoporosis contains the 3-nitropyridine derivative compound or salt thereof.

Abstract translation: 目的：提供2,6-位取代的3-硝基吡啶衍生物化合物，以抑制成骨细胞的形成并用于预防和治疗卵巢疏松症。 构成：新的2,6-取代的3-硝基衍生物化合物由化学式1表示。制备2,6-取代的3-硝基衍生物化合物的方法包括：将2,6-二氯-3- 硝基吡啶和5-氨基吲唑在碱存在下反应制备2（1H-吲唑-5-基）氨基-6-氯-3-硝基吡啶; 和2-甲基-2-咪唑啉，2-甲基咪唑，2-异丙基咪唑或5-甲基咪唑的胺化合物与2（1H-吲唑-5-基）氨基-6-氯-3- 硝基吡啶。 用于预防或治疗骨质疏松症的组合物含有3-硝基吡啶衍生物化合物或其盐。

公开(公告)号：KR1020100067046A

公开(公告)日：2010-06-18

申请号：KR1020090119519

申请日：2009-12-04

Applicant: 동화약품주식회사

Inventor： 유제만 ,  이진수 ,  박휘정 ,  황연하 ,  김기윤

IPC: C07D213/16 ,  C07D213/53 ,  A61K31/44 ,  A61P19/10

CPC classification number: C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14

Abstract: PURPOSE: A 3-nitropyridine derivative compound which is substituted at 2,6-site is provided to suppress differentiation of osteoclast and to prevent and treat osteoporosis. CONSTITUTION: A 3-nitropyridine derivative compound which is substituted at 2,6-site is denoted by chemical formula 1. A method for preparing the 3-nitropyridine derivative compound comprises: a step of reacting aniline compound of chemical formula 3 with 2,6-dichloro-3-nitropyridine under the presence of base to obtain a 6-chloro-3-nitropyridine derivative compound of chemical formula 4; and a step of reacting amine compound of chemical formula 5 with a compound of chemical formula 4 to obtain the 3-nitropyridine derivative compound. A pharmaceutical composition for preventing or treating osteoporosis contains the 3-nitropyridine derivative or pharmaceutically acceptable salt as an active ingredient.

Abstract translation: 目的：提供在2,6位取代的3-硝基吡啶衍生物化合物，以抑制破骨细胞的分化和预防和治疗骨质疏松症。 构成：在2,6-位取代的3-硝基吡啶衍生物化合物由化学式1表示。制备3-硝基吡啶衍生物化合物的方法包括：使化学式3的苯胺化合物与2,6- - 二氯-3-硝基吡啶在碱存在下反应，得到化学式4的6-氯-3-硝基吡啶衍生物化合物; 和使化学式5的胺化合物与化学式4的化合物反应以获得3-硝基吡啶衍生物化合物的步骤。 用于预防或治疗骨质疏松症的药物组合物含有3-硝基吡啶衍生物或药学上可接受的盐作为活性成分。

公开(公告)号：KR1020100014173A

公开(公告)日：2010-02-10

申请号：KR1020090070534

申请日：2009-07-31

Applicant: 동화약품주식회사

Inventor： 이진수 ,  황연하 ,  유제만 ,  박재훈 ,  정덕균

IPC: A61K31/426 ,  A61P19/10 ,  A61K31/663

CPC classification number: A61K31/426 ,  A61K31/663 ,  A61K2300/00

Abstract: PURPOSE: A composition for preventing and treating osteoporosis is provided to suppress osteoclast and bone absorption by using two kinds of compounds. CONSTITUTION: A composition for preventing or treating osteoporosis contains N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thizole-4-yl)phenoxy]pentoxy}benzamidine of chemical formula 1, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazole-4-yl)phenoxy]pentoxy}benzamidine compound of chemical formula 2, alendronic acid of chemical formula 3 or its salt as an active ingredient.

Abstract translation: 目的：提供一种预防和治疗骨质疏松症的组合物，以通过使用两种化合物来抑制破骨细胞和骨吸收。 构成：用于预防或治疗骨质疏松症的组合物含有化学式1的N-羟基-4- {5- [4-（5-异丙基-2-甲基-1,3-噻唑-4-基）苯氧基]戊氧基}苄脒 ，化学式2的4- {5- [4-（5-异丙基-2-甲基-1,3-噻唑-4-基）苯氧基]戊氧基}苄脒化合物，其化学式3的阿仑膦酸或其盐作为 有效成分。

公开(公告)号：KR1020030008653A

公开(公告)日：2003-01-29

申请号：KR1020010043489

申请日：2001-07-19

Applicant: 동화약품주식회사 ,  서홍석

Inventor： 이진수 ,  김판수 ,  황연하 ,  유제만 ,  정용호 ,  서홍석 ,  김도희 ,  박용엽

IPC: A61K31/166

Abstract: PURPOSE: Provided is N,N-diisopropyl-4-(7-(4-aminophenoxy)heptoxy)-3-methoxybenzamide(DW1259) which has leukotriene-B4 receptor antagonistic action and has excellent effects on inhibition of bone absorption by effectively inhibiting the function of osteoclast cells. CONSTITUTION: The agent for prophylaxis and treatment of osteoporosis contains an effective amount of N,N-diisopropyl-4-(7-(4-aminophenoxy)heptoxy)-3-methoxybenzamide of formula(1). The compound has an excellent inhibition effect on a differentiation, formation, fusion process and bone absorption function of osteoclast cells, is excellent in an inhibition function of osteoclast cells as compared to any compound such as DW1231, DW1234, DW1166, DW1235 having structural similarity as well as HS-1141 and CGS-25019C and has increased efficacy in increasing the activity of osteoblast cells.

Abstract translation: 目的：提供具有白三烯-B4受体拮抗作用的N，N-二异丙基-4-（7-（4-氨基苯氧基）庚氧基）-3-甲氧基苯甲酰胺（DW1259），并且通过有效抑制 破骨细胞功能。 构成：用于预防和治疗骨质疏松症的药物含有有效量的式（1）的N，N-二异丙基-4-（7-（4-氨基苯氧基）乙氧基）-3-甲氧基苯甲酰胺。 该化合物对破骨细胞的分化，形成，融合过程和骨吸收功能具有优异的抑制作用，与​​具有结构相似性的任何化合物如DW1231，DW1234，DW1166，DW1235相比，破骨细胞的抑制功能优异 以及HS-1141和CGS-25019C，并且增加了成骨细胞活性的功效。

公开(公告)号：KR1020020034759A

公开(公告)日：2002-05-09

申请号：KR1020000065270

申请日：2000-11-03

Applicant: 동화약품주식회사

Inventor： 황순봉 ,  윤성준 ,  김종우 ,  이경재 ,  황연하 ,  윤승원

IPC: C12N7/01

CPC classification number: C12N7/00 ,  C12N2710/14011 ,  C12Q1/68

Abstract: PURPOSE: Provided are a detecting method of hepatitis C virus(HCV) using recombinant mixed antigens derived from HCV and a diagnostic kit thereof, particularly by immuno chromatography using recombinant mixed antigens including core, NS3 and NS5A proteins of HCV gene as main components. CONSTITUTION: A recombinant Baculovirus(KCCM 10218) is manufactured by cotransfection of Baculovirus transfer vector including HCV derived core protein gene. HCV derived core protein is expressed from the recombinant Baculovirus(KCCM 10218) and has amino acid sequence of SEQ ID NO: 8. A recombinant Baculovirus(KCCM 10219) is manufactured by cotransfection of Baculovirus transfer vector including HCV derived NS3 protein gene. HCV derived NS3 proteins expressed from the recombinant Baculovirus(KCCM 10219) and has amino acid sequence of SEQ ID NO:9. An E.coli transformant(KCCM 10217) is transformed with a recombinant expression vector including HCV derived NS5A protein gene. HCV derived NS5A protein is expressed from the transformant and has amino acid sequence of SEQ ID NO: 10. The HCV diagnostic kit contains a mixed antigen consisting of core, NS3 and NS5A proteins derived from HCV.

Abstract translation: 目的：提供使用HCV衍生的重组混合抗原的丙型肝炎病毒（HCV）的检测方法及其诊断试剂盒，特别是使用包含HCV基因的核心，NS3和NS5A蛋白的重组混合抗原的免疫色谱作为主要成分。 构成：通过共转染包括HCV衍生的核心蛋白基因的杆状病毒转移载体来制备重组杆状病毒（KCCM 10218）。 HCV衍生的核心蛋白由重组杆状病毒（KCCM 10218）表达并具有SEQ ID NO：8的氨基酸序列。通过共转染包含HCV衍生的NS3蛋白基因的杆状病毒转移载体来制备重组杆状病毒（KCCM 10219）。 由重组杆状病毒（KCCM 10219）表达的HCV衍生的NS3蛋白，具有SEQ ID NO：9的氨基酸序列。 用包含HCV衍生的NS5A蛋白基因的重组表达载体转化大肠杆菌转化体（KCCM 10217）。 HCV衍生的NS5A蛋白由转化体表达，并具有SEQ ID NO：10的氨基酸序列。HCV诊断试剂盒含有由核心，NS3和源自HCV的NS5A蛋白组成的混合抗原。

公开(公告)号：KR1020100066868A

公开(公告)日：2010-06-18

申请号：KR1020080125361

申请日：2008-12-10

Applicant: 동화약품주식회사

Inventor： 유제만 ,  이진수 ,  박휘정 ,  황연하 ,  정덕균

IPC: C07D213/72 ,  C07D213/64 ,  C07D213/16

CPC classification number: C07D213/74

Abstract: PURPOSE: A 3-nitropyridine derivative compound in which 2,6-site is substituted is provided to suppress osteoclast formation and to prevent and treat osteoporosis. CONSTITUTION: A 3-nitropyridine derivative compound in which 2,6-site is substituted is denoted by chemical formula 1. A method for preparing the 3-nitropyridine derivative comprises: and a step of reacting 2,6dichloro-3-nitropyridine and 5-amino triazole under the presence of base to obtain 2-(1H-benzotriazole-5-yl)amino-6-chloro-3-nitropyridine with HNR_2(CH_2)nR1 amine compound to obtain 3-nitropyridine derivative in which 1,6 site of chemical formula 1. A pharmaceutical composition for preventing or treating osteoporosis contains 3-nitropyridine derivative compound or pharmaceutically acceptable salt as an active ingredient.

Abstract translation: 目的：提供2,6-取代的3-硝基吡啶衍生物，以抑制破骨细胞形成和预防和治疗骨质疏松症。 构成：其中2,6-位被取代的3-硝基吡啶衍生物化合物由化学式1表示。制备3-硝基吡啶衍生物的方法包括：使2,6-二氯-3-硝基吡啶与5- 氨基三唑在碱存在下反应，得到2-（1H-苯并三唑-5-基）氨基-6-氯-3-硝基吡啶与HNR 2（CH 2）n R 1胺化合物，得到3-硝基吡啶衍生物，其中， 化学式1.用于预防或治疗骨质疏松症的药物组合物含有3-硝基吡啶衍生物化合物或药学上可接受的盐作为活性成分。

公开(公告)号：KR100875596B1

公开(公告)日：2008-12-23

申请号：KR1020070009859

申请日：2007-01-31

Applicant: 동화약품주식회사

Inventor： 유제만 ,  이진수 ,  진영구 ,  이기영 ,  박재훈 ,  황연하 ,  구세광

IPC: C07D277/22 ,  C07D413/04 ,  C07D401/04 ,  A61P19/10

CPC classification number: C07D417/04 ,  C07D277/28 ,  C07D417/12

Abstract: The present invention relates to a novel benzamidine derivative, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzamidine derivative of the present invention effectively inhibits osteoclast differentiation at an extremely low concentration, and greatly increases the trabecular bone volume, and thus it can be advantageously used for the prevention and treatment of osteoporosis.

Abstract translation: 本发明涉及一种新的苯甲脒衍生物，其制备方法以及包含其的药物组合物。 本发明的苯甲脒衍生物以极低浓度有效地抑制破骨细胞分化，并且大大增加了骨小梁的体积，因此可有利地用于预防和治疗骨质疏松症。